Transgenic Angiopoietin-Like (Angptl)4 Overexpression and Targeted Disruption of Angptl4 and Angptl3: Regulation of Triglyceride Metabolism
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Lipoprotein lipase (LPL) is a key regulator of triglyceride clearance. Its coordinated regulation during feeding and fasting is critical for maintaining lipid homeostasis and energy supply. Angiopoietin-like (Angptl)3 and Angptl4 are secreted proteins that have been demonstrated to regulate triglyceride metabolism by inhibiting LPL. We have taken a targeted genetic approach to generate Angptl4- and Angptl3-deficient mice as well as transgenic mice overexpressing human Angptl4 in the liver. The Angptl4 transgenic mice displayed elevated plasma triglycerides and reduced postheparin plasma (PHP) LPL activity. A purified recombinant Angptl4 protein inhibited mouse LPL and recombinant human LPL activity in vitro. In contrast to the transgenic mice, Angptl4-deficient mice displayed hypotriglyceridemia and increased PHP LPL activity, with greater effects in the fasted compared with the fed state. Angptl3-deficient mice also displayed hypotriglyceridemia with elevated PHP LPL activity, but these mice showed a greater effect in the fed state. Mice deficient in both Angptl proteins showed an additive effect on plasma triglycerides and did not survive past 2 months of age. Our results show that Angptl3 and Angptl4 function to regulate circulating triglyceride levels during different nutritional states and therefore play a role in lipid metabolism during feeding/fasting through differential inhibition of LPL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ANGPTL3 inhibits the lipoprotein lipase, which results in increased blood lipid levels [143–145].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [143]
In the citing paper
“Evinacumab is a monoclonal antibody inhibiting angiopoietin-like 3 (ANGPTL3).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [143]
In the citing paper
“In contrast to other pharmacological treatments, evinacumab’s MoA is therefore independent of the LDL-C receptor [143, 148], providing new options for more synergistic combination treatments.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [143]
In the citing paper
“Thus, Angptl4 knockout mice have reduced plasma triglycerides, whereas Angptl4 overexpressing mice have increased triglyceride levels [9,10].”
From Differential effects of angiopoietin-like 4 in brain and muscle on regulation of lipoprotein lipase activity (2015) · cites this paper as [9]
In the citing paper
“Conversely, ANGPTL4-deficient mice had lower than normal plasma triglycerides and higher postheparin-plasma LPL activity (16).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [16]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzyme kinetics; behavior and analysis of rapid equilibrium and steady state enzyme systems
(1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90021-3 · Cited by 2,972
Lipoprotein lipase: structure, function, regulation, and role in disease
Mead, J., Irvine, S., & Ramji, D. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0384-9 · Cited by 927
Merkel, M., Eckel, R. H., & Goldberg, I. J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200015-jlr200 · Cited by 522
Kersten, S., Mandard, S., Tan, N. S., Escher, P., Metzger, D., Chambon, P., Gonzalez, F. J., Desvergne, B., & Wahli, W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004029200 · Cited by 489
Angptl3 regulates lipid metabolism in mice
Koishi, R., Ando, Y., Ono, M., Shimamura, M., Yasumo, H., Fujiwara, T., Horikoshi, H., & Furukawa, H. (2002) · Nature Genetics · doi:10.1038/ng814 · Cited by 379
Yoon, J. C., Chickering, T. W., Rosen, E. D., Dussault, B., Qin, Y., Soukas, A., Friedman, J. M., Holmes, W. E., & Spiegelman, B. M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5343-5349.2000 · Cited by 356
Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203215200 · Cited by 339
Yoshida, K., Shimizugawa, T., Ono, M., & Furukawa, H. (2002) · Journal of Lipid Research · doi:10.1194/jlr.c200010-jlr200 · Cited by 317
Kim, I., Kim, H.-G., Kim, H. W., Kim, H.-H., Park, S. K., Uhm, C.-S., Lee, Z. H., & Koh, G. Y. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460603 · Cited by 284
Weinstock, P. H., Bisgaier, C. L., Aalto-Setälä, K., Radner, H., Ramakrishnan, R., Levak-Frank, S., Essenburg, A. D., Zechner, R., & Breslow, J. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118319 · Cited by 254
Cited by
Items 201–300 of 427
Oteng, A.-B., Bhattacharya, A., Brodesser, S., Qi, L., Tan, N. S., & Kersten, S. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m074278 · Cited by 34
Integrated Control of Fatty Acid Metabolism in Heart Failure
Li, X., & Bi, X. (2023) · Metabolites · doi:10.3390/metabo13050615 · Cited by 39
Vienberg, S. G., Kleinridders, A., Suzuki, R., & Kahn, C. R. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.003 · Cited by 33
“Thus, Angptl4 knockout mice have reduced plasma triglycerides, whereas Angptl4 overexpressing mice have increased triglyceride levels [9,10].”
BackgroundXenobiotic Receptor-Mediated Regulation of Intestinal Barrier Function and Innate Immunity
Ranhotra, H. S., Flannigan, K. L., Brave, M., Mukherjee, S., Lukin, D. J., Hirota, S. A., & Mani, S. (2016) · Nuclear Receptor Research · doi:10.11131/2016/101199 · Cited by 39
ANGPTL4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a
Jung, K. H., Son, M. K., YAN, H. H., Fang, Z., Kim, J.-Y., Kim, S. J., Park, J. H., Lee, J. E., Yoon, Y., Seo, M.-S., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911222 · Cited by 33
“Several studies have reported that ANGPTL4 knockout ( / ) mice display a 65–90% reduction in fasting TG levels and slightly reduced total cholesterol levels, in addition to decreased circulating VLDL and increased lipoprotein lipase activity (Koster et al, 2005).”
BackgroundAngiopoietin-like 3 inhibition of endothelial lipase is not modulated by angiopoietin-like 8
Sylvers-Davie, K. L., Segura-Roman, A., Salvi, A. M., Schache, K. J., & Davies, B. S. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100112 · Cited by 34
Therapeutic targets of triglyceride metabolism as informed by human genetics
Bauer, R. C., Khetarpal, S. A., Hand, N. J., & Rader, D. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.005 · Cited by 32
Nilsson, S. K., Anderson, F., Ericsson, M., Larsson, M., Makoveichuk, E., Lookene, A., Heeren, J., & Olivecrona, G. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.06.003 · Cited by 32
Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease?
Olshan, D. S., & Rader, D. J. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.01.012 · Cited by 30
Appraisal of hepatic lipase and lipoprotein lipase activities in mice
Dallinga-Thie, G. M., Zonneveld-de Boer, A. J., van Vark-van der Zee, L. C., van Haperen, R., van Gent, T., Jansen, H., De Crom, R., & van Tol, A. (2007) · Journal of Lipid Research · doi:10.1194/jlr.d700021-jlr200 · Cited by 30
“, apolipoprotein A-V (9), the angiopoetin-like proteins (10, 11), and the recently discovered glycosylphosphatidylinositol-anchored HDL binding protein 1 (12)].”
BackgroundmTORC1 restrains adipocyte lipolysis to prevent systemic hyperlipidemia
Paolella, L. M., Mukherjee, S., Tran, C. M., Bellaver, B., Hugo, M., Luongo, T. S., Shewale, S. V., Lu, W., Chellappa, K., & Baur, J. A. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.003 · Cited by 34
“LPL activity has been shown to be inhibited by Angptl4, in vitro and in vivo, which could account for differences in activity vs expression [45,46].”
BackgroundFasting-induced adipose factor/angiopoietin–like protein 4: a potential target for dyslipidemia?
Zandbergen, F., van Dijk, S., Müller, M., & Kersten, S. (2006) · Future Lipidology · doi:10.2217/17460875.1.2.227 · Cited by 29
Yokouchi, H., Eto, K., Nishimura, W., Takeda, N., Kaburagi, Y., Yamamoto, S., & Yasuda, K. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12097 · Cited by 29
“Although some ANGPTLs, including ANGPTL3 and ANGPTL6, exhibit angiogenic activity (Camenisch et al. 2002; Oike et al. 2004), the potential angiogenic activity of other family members, including ANGPTL2 (Dhanabal et al. 2002; Kubota et al. 2005) and ANGPTL4, is rather controversial.”
BackgroundPostprandial dysmetabolism: Too early or too late?
Pappas, C., Kandaraki, E., Tsirona, S., Kountouras, D., Kassi, G., & Diamanti‐Kandarakis, E. (2016) · HORMONES · doi:10.14310/horm.2002.1697 · Cited by 33
Can targeting ANGPTL proteins improve glucose tolerance?
Davies, B. S. J. (2018) · Diabetologia · doi:10.1007/s00125-018-4604-4 · Cited by 31
“There appears to be no changes in plasma glucose or insulin levels in Angptl4 knockout mice or in humans with the loss-of-function E40K allele of ANGPTL4 [2, 6].”
Deng, M., Kutrolli, E., Sadewasser, A., Michel, S., Joibari, M. M., Jaschinski, F., Olivecrona, G., Nilsson, S. K., & Kersten, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100237 · Cited by 31
“In the first study using whole-body ANGPTL4-null mice, plasma TG levels were more strongly reduced in male mice than in female mice (51).”
Lu, Q., Zou, W., Chen, B., Zou, C., Zhao, M., & Zheng, Z. J. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3187-8 · Cited by 31
Omega-3 long-chain fatty acids strongly induce angiopoietin-like 4 in humans
Brands, M., Sauerwein, H. P., Ackermans, M. T., Kersten, S., & Serlie, M. J. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m030049 · Cited by 32
Yang, L., Yu, C., Wang, X., Yuan, S., Zhang, L., Lang, J., Zhao, D., & Feng, Y. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005973 · Cited by 24
“Because of increased LPL activity, ANGPTL4-null mice are featured as having lower triglycerides in the blood.(11) The inverse correlation between ANGPTL4 and high-density lipoprotein-cholesterol HDL-c (high-density lipoprotein-cholesterol) has been reported in European and American populations.”
BackgroundGong, D., Zhang, Q., Chen, L., Yu, X.-H., Wang, G., Zou, J., Zheng, X., Zhang, D., Yin, W., & Tang, C. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.11.009 · Cited by 28
“However, knockdown of FOXO3a significantly but not completely suppressed shCCDC80-induced increase in the expression levels of LPL, suggesting that FOXO3a at least partially contributes to the regulatory effect of CCDC80 on LPL expression.”
BackgroundInfluentialA VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice
Fowler, A., Sampson, M. L., Remaley, A. T., & Chackerian, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.077 · Cited by 29
Muniyappa, R., Abel, B. S., Asthana, A., Walter, M. F., Cochran, E. K., Remaley, A. T., Skarulis, M. C., Görden, P., & Brown, R. J. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.002 · Cited by 28
Popova, P., Vasilyeva, L., Tkachuck, A., Puzanov, M., Golovkin, A., Bolotko, Y., Pustozerov, E., Vasilyeva, E., Li, O., Zazerskaya, I., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/6481658 · Cited by 27
“ANGPTL4 is involved in the regulation of multiple physiological processes, including energy metabolism [8], plasma glucose level and tolerance regulation [9], fat storage, and lipid metabolism [10].”
BackgroundZhang, L., Shannon, C. E., Bakewell, T. M., Abdul‐Ghani, M. A., Fourcaudot, M. J., & Norton, L. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00339.2019 · Cited by 29
Adachi, H., Kondo, T., Koh, G. Y., Nagy, A., Oike, Y., & Araki, E. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.110 · Cited by 27
“The Angptl4 KO mice, in contrast, displayed a hypolipidemic phenotype due to increased LPL activity, which increased clearance of VLDL from the circulation [9] [8].”
BackgroundHepatocyte β‐Klotho regulates lipid homeostasis but not body weight in mice
Kobayashi, K., Tanaka, T., Okada, S., Morimoto, Y., Matsumura, S., Manio, M. C. C., Inoue, K., Kimura, K., Yagi, T., Saito, Y., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-274449 · Cited by 28
“Recent studies have observed that angiopoietin-like proteins (ANGPTLs) 3, 4, and 8, members of the ANGPTL family, are involved in the maintenance of plasma triglyceride levels (29, 40).”
BackgroundYang, H. J., Xiao, L., & Xu, D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07001-0 · Cited by 26
“Because of the weak expression of LPL in the liver, TRL residues are not metabolized by LPL but are taken up by receptor-mediated endocytosis, and some of the lipids are hydrolyzed by hepatic lipase (HL) [38, 60].”
BackgroundCirculating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity
Sun, T., Zhan, W., Wei, L., Xu, Z., Li, F., Yang, Z., Wang, C., & Zhang, J. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01580-z · Cited by 25
“However, some studies have revealed a reduction in plasma triglyceride levels in mice with ANGPTL4 deficiency and inactivation [24, 25].”
BackgroundStapleton, C. M., Joo, J. H., Kim, Y.-S., Liao, G., Panettieri, R. A., & Jetten, A. M. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.12.004 · Cited by 25
Bouazzi, L., Sproll, P., Eid, W., & Biason‐Lauber, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-53370-4 · Cited by 28
Melnyk, R. A., Tam, J., Boie, Y., Kennedy, B. P., & Percival, M. D. (2009) · American Journal of Nephrology · doi:10.1159/000220260 · Cited by 29
“ANGPTL4, which is highly upregulated by renin and prorenin, has been shown previously to regulate triglyceride clearance and negatively regulate the expression of lipoprotein lipase, a close homologue of LIPG. Thus, an increase in expression of ANGPTL4 is expected to be associated with an increase in plasma triglyceri…”
BackgroundLandfors, F., Chorell, E., & Kersten, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100313 · Cited by 25
“Studies in genetically modified mice have shown that ANGPTL4 reduces LPL activity and plasma TG clearance in adipose tissue during fasting, thereby directing circulating TG to other tissues (7-14).”
BackgroundANGPLT3: A novel modulator of lipid metabolism
Hassan, M. S. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.6 · Cited by 29
“ANGPTL4-deficient mice displayed hypotriglyceridemia and elevated post heparin LPL activity with greater effects in the fasted compared with the fed state.(32) However, ANGPTL3-deficient mice displayed hypotriglyceridemia with a greater effect in the fed state.”
BackgroundPaeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice
Xiao, H., Liang, L., Luo, Z.-F., & Sun, Z. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.006 · Cited by 25
Staiger, H., Machicao, F. E., Werner, R., Guirguis, A., Weisser, M., Stefan, N., Fritsche, A., & Häring, H. (2008) · Metabolism · doi:10.1016/j.metabol.2007.12.007 · Cited by 25
“Within adipose tissue, ANGPTL4 obviously exerts auto-/paracrine actions and affects lipid metabolism: (a) via inhibition of lipoprotein lipase activity [6], ANGPTL4 blocks the clearance of very low-density lipoproteins and chylomicrons and thus provokes hypertriglyceridemia [5-9]; (b) ANGPTL4 stimulates adipose tissue…”
BackgroundChronic high-fat feeding and prolonged fasting in liver-specific ANGPTL4 knockout mice
Spitler, K. M., Shetty, S. K., Cushing, E. M., Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00144.2021 · Cited by 23
Evinacumab: Mechanism of action, clinical, and translational science
Dingman, R., Bihorel, S., Gusarova, V., Mendell, J., & Pordy, R. (2024) · Clinical and Translational Science · doi:10.1111/cts.13836 · Cited by 23
Cai, Y., Fan, Y., Song, E., Wang, Y., Xu, A., Vanhoutte, P. M., & Tang, E. H. C. (2015) · The FASEB Journal · doi:10.1096/fj.15-274597 · Cited by 25
“Forexample,micewithoverexpressionofangiopoietin like 4, a direct inhibitor of LPL (43), or mice with deletion of glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1, a participant in the docking of triglyceride-rich lipoproteins to LPL (44), exhibit hypertriglyceridemia caused by impaired…”
BackgroundBaranowski, T., Kralisch, S., Bachmann, A., Lössner, U., Kratzsch, J., Blüher, M., Stümvoll, M., & Faßhauer, M. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1267917 · Cited by 24
Dotterweich, J., Schlegelmilch, K., Keller, A., Geyer, B., Schneider, D., Zeck, S., Tower, R. J., Ebert, R., Jakob, F. J., & Schütze, N. (2016) · Bone · doi:10.1016/j.bone.2016.08.006 · Cited by 24
Janssen, A. W. F., Dijk, W., Boekhorst, J., Kuipers, F., Groen, A. K., Lukovac, S., Hooiveld, G. J. E. J., & Kersten, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.07.005 · Cited by 25
ANGPTL3 inhibits renal cell carcinoma metastasis by inhibiting VASP phosphorylation
Zhao, T., Liang, X., Chen, J., Bao, Y., Wang, A., Gan, X., Lu, X. L., & Wang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.06.120 · Cited by 23
Fortunato, I. M., Pereira, Q. C., Oliveira, F. D. S., Alvarez, M. C., dos Santos, T. W., & Ribeiro, M. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031803 · Cited by 26
Noto, D., Arca, M., Tarugi, P., Cefalu, A. B., Barbagallo, C. M., & Averna, M. R. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0931-4 · Cited by 25
Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis
Lu, X. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190621120523 · Cited by 22
Angiopoietin-like 8 (ANGPTL8) expression is regulated by miR-143-3p in human hepatocytes
DiStefano, J. K. (2018) · Gene · doi:10.1016/j.gene.2018.09.041 · Cited by 24
Hjelholt, A. J., Søndergaard, E., Pedersen, S. B., Møller, N., Jessen, N., & Jørgensen, J. O. L. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154188 · Cited by 23
Larsson, M., Caraballo, R., Ericsson, M., Lõokene, A., Enquist, P., Elofsson, M., Nilsson, S. K., & Olivecrona, G. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.06.114 · Cited by 20
Transcriptome Analysis of Landrace Pig Subcutaneous Preadipocytes during Adipogenic Differentiation
Zhao, X., Chen, S., Tan, Z., Wang, Y., Zhang, F., Yang, T., Liu, Y., Ao, H., Xing, K., & Wang, C. (2019) · Genes · doi:10.3390/genes10070552 · Cited by 24
Angiopoietin-like proteins and postprandial partitioning of fatty acids
DiDonna, N., Chen, Y. Q., & Konrad, R. J. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000798 · Cited by 20
“Alternatively, when ANGPTL3 and ANGPTL4 are both knocked out in mice, lethality occurs because of an inability of ANGPTL3/4/8 proteins to inhibit LPL [20].”
BackgroundSex-specific differences in hepatic steatosis in obese spontaneously hypertensive (SHROB) rats
Dong, Q., Kuefner, M., Deng, X., Bridges, D., Park, E. A., Elam, M. B., & Raghow, R. (2018) · Biology of Sex Differences · doi:10.1186/s13293-018-0202-x · Cited by 20
Chen, L., Lei, Y., Lu, C., Liu, D., Ma, W., Lu, H., & Wang, Y. (2024) · Food & Function · doi:10.1039/d4fo00502c · Cited by 22
Okamoto, H., Cavino, K., Na, E., Krumm, E. A., Kim, S. B., Stevis, P. E., Harp, J. B., Murphy, A. J., Yancopoulos, G. D., & Gromada, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620989114 · Cited by 21
“As expected (31, 32), Angptl4 mice had nearly one-half of the circulating triglycerides of wild-type mice (Fig.”
Heitel, P., Gellrich, L., Heering, J., Goebel, T., Kahnt, A. S., Proschak, E., Schubert‐Zsilavecz, M., & Merk, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-31833-4 · Cited by 23
Bigford, G. E., Bracchi-Ricard, V. C., Nash, M. S., & Bethea, J. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041073 · Cited by 21
“However, FIAF has also been shown to have beneficial effects on triglyceride lipid metabolism [90], fatty acid oxidation and lipolysis [91] as well as plasma glucose levels and glucose tolerance [92], suggesting an important role in peripheral metabolic homeostasis.”
BackgroundPotential role of ANGPTL4 in cancer progression, metastasis, and metabolism: a brief review
Park, M. S., Kim, S. E., Lee, P., Lee, J., Jung, K. H., & Hong, S. (2024) · BMB Reports · doi:10.5483/bmbrep.2024-0082 · Cited by 23
“ANGPTL4 has been reported to play an important role in metabolic processes, most notably in lipid metabolism, by degrading triglycerides (TGs) (75, 76).”
BackgroundJiang, Y., Xie, M., Fan, W., Xue, J., Zhou, Z., Tang, J., Chen, G., & Hou, S. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00710 · Cited by 21
Expression of Angiopoietin-Like 3 Associated with Puromycin-Induced Podocyte Damage
Jia, R., Xu, H. M., Li, S., Yang, H., & Chuan-ming, H. (2010) · Nephron Experimental Nephrology · doi:10.1159/000313829 · Cited by 19
Wu, G., Zhang, L., Gupta, J., Olivecrona, G., & Olivecrona, T. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00634.2006 · Cited by 19
“triglyceride metabolism that function by modulating LPL activity ( 18 ).”
BackgroundYe, Q., Tian, G.-P., Cheng, H.-P., Zhang, X., Ou, X., Yu, X.-H., Tan, R.-Q., Yang, F.-Y., Gong, D., Huang, C., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.40212 · Cited by 18
RetractedBailey, T., Simeon, J., & Thrush, J. (2021) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_20_20 · Cited by 20
“, 2005 reported that ANGPTL4 overexpression in mice caused hyperlipidemia and elevated triglycerides in vivo.[33,34] One mouse in our study exhibited hyperlipidemia (data not shown), indicating that ANGPTL4 secreted by TNBC may alter the lipogenic profile within an Figure 5: Angiopoietin‐like protein 4 driven primary…”
Katanasaka, Y., Saito, A., Sunagawa, Y., Sari, N., Funamoto, M., Shimizu, S., Shimizu, K., Akimoto, T., Ueki, C., Kitano, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092449 · Cited by 20
“It has been reported that ANGPTL4 knockout mice exhibit increased peripheral LPL activity and decreased TG levels [9].”
BackgroundRegulation of Energy Balance by the Hypothalamic Lipoprotein Lipase Regulator Angptl3
Kim, H.-K., Shin, M., Youn, B., Kang, G. M., Gil, S. Y., Lee, C. H., Choi, J. H., Lim, H. S., Yoo, H. J., & Kim, M.-S. (2014) · Diabetes · doi:10.2337/db14-0647 · Cited by 19
“Supporting these actions, Angptl3-deficient mice display lower circulating TG levels (20,21), whereas Angptl3 administration results in increased plasma lipid levels (17).”
BackgroundHess, A. L., Carayol, J., Blædel, T., Hager, J., Cara, A. D., Astrup, A. V., Saris, W. H. M., Larsen, L. H., & Valsesia, A. (2018) · Genes & Nutrition · doi:10.1186/s12263-018-0597-3 · Cited by 19
“But the functional evidence is derived from animal studies [33, 34] and the exact inhibitory mechanisms of ANGPTL3 on LPL in humans are not fully understood.”
BackgroundRuhanen, H., Haridas, P. A. N., Jauhiainen, M., & Olkkonen, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158791 · Cited by 19
The Hyplip2 locus causes hypertriglyceridemia by decreased clearance of triglycerides
Moen, C. J. A., Tholens, A., Voshol, P. J., de Haan, W., Havekes, L. M., Gargalovic, P. S., Lusis, A. J., van Dijk, K. W., Frants, R. R., Hofker, M. H., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700009-jlr200 · Cited by 20
“The fact that Hyplip2 primarily increases TG in the fed state, whereas the effects of Angptl4 on TG levels are most prominent in the fasted state ( 40 ), may argue against an interaction between Hyplip2 and angptl4.”
van der Kolk, B. W., Goossens, G. H., Jocken, J. W. E., Kersten, S., & Blaak, E. E. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4285 · Cited by 17
A Generalized Genetic Random Field Method for the Genetic Association Analysis of Sequencing Data
Li, M., He, Z., Zhang, M., Zhan, X., Wei, C., Elston, R. C., & Lu, Q. L. (2014) · Genetic Epidemiology · doi:10.1002/gepi.21790 · Cited by 16
Intrinsic and extrinsic regulation of cardiac lipoprotein lipase following diabetes
Wang, Y., & Rodrigues, B. B. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.11.007 · Cited by 17
Chen, N., Ma, Y., Yang, T., Lin, F., Fu, W., Xu, Y., Li, F., Li, J. Y., & Gao, S. (2015) · animal · doi:10.1017/s1751731115000658 · Cited by 16
“The ANGPTL3 rs12130333 polymorphism was strongly associated with Fredrickson hyperlipoproteinemia type 5 (Köster et al., 2005).”
BackgroundNakamoto, M., Ishihara, K., Watanabe, T., Hirosue, A., Hino, S., Shinohara, M., Nakayama, H., & Nakao, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169225 · Cited by 26
Yang, Q., Yin, R., Cao, X., Huang, F., Zhou, Y., & Chen, W. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0308-5 · Cited by 17
Genetics of Lipid Traits and Relationship to Coronary Artery Disease
Keenan, T. E., & Rader, D. J. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0396-9 · Cited by 19
“Mechanistic studies demonstrate that the ANGPTL3 protein reversibly blocks the LPL-mediated breakdown of TG-rich particles [56, 57] and is most active after eating [58].”
ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice
Xiao, H., Wang, J., & Sun, Z. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.11.003 · Cited by 19
Janečková, L., Kostovcikova, K., Švec, J., Šťastná, M., Strnad, H., Kolář, M., Hudcovic, T., Stančíková, J., Turečková, J., Dibus, N., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071581 · Cited by 18
Ruhanen, H., Haridas, P. A. N., Minicocci, I., Taskinen, J., Palmas, F., Costanzo, A. D., D’Erasmo, L., Metso, J., Partanen, J., Dalli, J., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158679 · Cited by 18
“They are potent inhibitors of LPL, which hydrolyzes triglyceride rich lipoproteins (TRLs) [4;5].”
BackgroundDing, S., Lin, Z., Zhang, X., Jia, X., Li, H., Fu, Y., Wang, X., Zhu, G., Lu, G., Xiao, W., et al. (2023) · Immunology · doi:10.1111/imm.13650 · Cited by 16
“The TAG levels of blood decreased in fed or fasted male ANGPTL4 / mice and in fasted female ANGPTL4 / mice [29].”
BackgroundTargeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside
Ling, P., Zheng, X., Luo, S., Ge, J., Xu, S., & Weng, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14450 · Cited by 16
“Several studies have shown that the elevation of LPL activity in Angptl3 / mice only occurred under conditions of feeding and refeeding, but not in the fasting state.(26,41) Conversely, the expression of ANGPTL3 in liver tissues was not appreciably affected by nutritional status.”
BackgroundInfluentialCardiac lipoprotein lipase activity in the hypertrophied heart may be regulated by fatty acid flux
Hauton, D., & Caldwell, G. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.12.004 · Cited by 15
Cohen, C. D., Blasio, M. J. D., Farrugia, G. E., Dona, M. S. I., Hsu, I., Prakoso, D., Kiriazis, H., Krstevski, C., Nash, D. M., Li, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107759 · Cited by 15
Gao, W.-Y., Chen, P., Hsu, H., Liou, J.-W., Wu, C., Wu, M., & Yen, J.-H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116598 · Cited by 14
Ma, L., Ballantyne, C. M., Brautbar, A., & Keinan, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092469 · Cited by 20
“Interestingly, ANGPTL4 encodes a protein that inhibits hepatic lipase’s triglyceride hydrolyzing activity [33].”
Backgroundde Armas‐Rillo, L., Quevedo-Abeledo, J. C., Hernández-Hernández, V., de Vera-González, A., Delgado, A. G., García-Dopico, J. A., González-Gay, M. Á., & Ferraz‐Amaro, I. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02784-z · Cited by 14
“Among the endogenous modulators of LPL are ANGPTL4 that inhibits LPL and modulates the uptake of free fatty acids in fasting and fed states [2] and ApoC3 that also inhibits the lipolysis of triglyceride-rich lipoproteins by LPL [3].”
BackgroundOntogeny of angiopoietin‐like protein 1, 2, 3, 4, 5, and 7 genes during chick embryonic development
Niki, D., Katsu, K., & Yokouchi, Y. (2009) · Development Growth & Differentiation · doi:10.1111/j.1440-169x.2009.01145.x · Cited by 14
“In addition, several members (ANGPTL3, 4, and 6) serve crucial functions in lipid metabolism and possibly glucose metabolism (Koishi et al. 2002; Koster et al. 2005; Oike et al. 2005; Sukonina et al. 2006).”
BackgroundOrtega, H., van Poppel, M. N. M., Desoyé, G., & Herrera, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-29731-w · Cited by 14
Angiopoietin-like 4 governs diurnal lipoprotein lipase activity in brown adipose tissue
van Eenige, R., Panhuis, W. I. H., Schönke, M., Jouffe, C., Devilee, T. H., Siebeler, R., Streefland, T. C. M., Sips, H. C. M., Pronk, A. C. M., Vorderman, R. H. P., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101497 · Cited by 16
“Angptl4 KO mice do not fully express the Angptl4 gene, resulting in a non-functional ANGPTL4 protein [54,55], whereas Angptl4 Tg mice overexpress Angptl4 under its own promotor [56].”
BackgroundMethodHoffmann, W. G., Chen, Y., Schwartz, C. S., Barber, J. L., Dev, P. K., Reasons, R. J., Miranda-Maravi, S., Armstrong, B., Gerszten, R. E., Silbernagel, G., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100495 · Cited by 16
ANGPTL4 induces Kupffer cell M2 polarization to mitigate acute rejection in liver transplantation
Huang, W., Jiang, L., Jiang, Y., Li, S., Liu, W., Zong, K., Peng, D., Wu, Z., & Huang, Z. (2025) · Scientific Reports · doi:10.1038/s41598-024-81832-x · Cited by 16
Vahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14
Angiopoietin-like 3 regulates hepatocyte proliferation and lipid metabolism in zebrafish
Lee, S.-H., So, J., Kim, H.-T., Choi, J., Lee, M., Choi, S., Kim, C., & Kim, J. M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.099 · Cited by 13
Cardiomyocyte-endothelial cell control of lipoprotein lipase
Chiu, A. P., Wan, A., & Rodrigues, B. B. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.03.016 · Cited by 14
Schinzari, F., Vizioli, G., Campia, U., Tesauro, M., & Cardillo, C. (2021) · Biomedicines · doi:10.3390/biomedicines9081037 · Cited by 13
“Not surprisingly, transgenic mice with overexpression of Angptl3 or Angptl4 have increased plasma triglyceride levels [5,6]; knockout animals, by contrast, have reduced levels of triglyceride-rich lipoproteins and increased LPL activity [7,8].”
BackgroundFlores‐León, M., Alcaraz, N., Pérez‐Domínguez, M., Torres‐Arciga, K., Rebollar‐Vega, R., Rosa-Velázquez, I. A. D. L., Arriaga-Canon, C., Herrera, L. A., Arias, C., & González‐Barrios, R. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02434-6 · Cited by 14
Son, Y., & Paton, C. M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.987977 · Cited by 12
Using human genetics to predict the effects and side-effects of drugs
Stender, S., & Tybjærg‐Hansen, A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000280 · Cited by 13
Dikker, O., Dağ, N. Ç., Şahin, M., Türkkan, E., & Dağ, H. (2019) · Cytokine · doi:10.1016/j.cyto.2019.154802 · Cited by 12
Beneficial effect of 3,4,5,6-tetrahydroxyxanthone on dyslipidemia in apolipoprotein E-deficient mice
Xiao, H., Sun, Z., Lu, X., Li, D.-Z., Xu, J.-P., & Hu, Y.-P. (2008) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y08-091 · Cited by 13
Self-citationBrain-acting hepatokines: its impact on energy balance and metabolism
Giovanini, L., Wanionok, N. E., Perelló, M., & Cornejo, M. P. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1589110 · Cited by 16
Alnassar, N., Hillman, C., Fontana, B. D., Robson, S. C., Norton, W., & Parker, M. O. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.08.004 · Cited by 9
Lightbourne, M., Wolska, A. T., Abel, B. S., Rother, K. I., Walter, M. F., Kushchayeva, Y. S., Auh, S., Shamburek, R. D., Remaley, A. T., Muniyappa, R., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa191 · Cited by 11
“Although ANGPTL4 is known to inhibit LPL and higher ANGPTL4 is associated with increased triglycerides [65-68], we did not find an association between ANGPTL4 and triglycerides in the current study.”
Background
Metadata
- Authors
- Köster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., Heuer, J. G., Jaskunas, S. R., & Eacho, P.
- Affiliations
- Eli Lilly (United States) (US)
- Takeda Oncology (United States) (US)
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2005-11-01
- Volume
- 146
- Issue
- 11
- Pages
- 4943-4950
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2117617326
- Semantic Scholar
- 6382419c744ba19464b065395484df9cb3cf3eaf
- Cited by
- 427
- References
- 36
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 14 · 2023: 15 · 2022: 11 · 2021: 41 · 2020: 26 · 2019: 20 · 2018: 33 · 2017: 21 · 2016: 23 · 2015: 26 · 2014: 27 · 2013: 29 · 2012: 22
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- ANGPTL4, ANGPTL3, lipoprotein lipase, triglyceride metabolism, hypotriglyceridemia, plasma triglycerides, lipoprotein lipase inhibition, fasting and feeding, lipid homeostasis, knockout mice, transgenic mice
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 4, Angiopoietin-Like Protein 3, Animals, Fasting, Heparin, Humans, Hyperlipidemias, Lipoprotein Lipase, Mice, Transgenic, Recombinant Proteins, Triglycerides, Survival Analysis, Mice, Knockout, Postprandial Period, Intercellular Signaling Peptides and Proteins, Angiopoietins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.